# US 2010/0168121 A1 · Compounds with 5-ht1a activity useful for treating disorders of the outer retina

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168121 A1
- Document ID: US20100168121A1
- Status: Published application
- Kind: A1
- Application number: 12/719,152
- Filed: 2010-03-08
- Published: 2010-07-01
- Earliest claimed: 2000-03-17
- Assignees: Alcon Inc.
- Inventors: Robert J. Collier, JR.; Michael A. Kapin; Mark R. Hellberg; Thomas R. Dean
- Web page: https://patentgrep.com/patent/US20100168121A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61P 27/02: Ophthalmic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compositions and methods for treating disorders of the outer retina with compounds with 5-HT1A agonist activity are disclosed.

## Claims

### Claim 1

A method for treating disorders of the outer retina which comprises administering a pharmaceutically effective amount of a compound with 5-HT1A agonist activity.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound is selected from the group consisting of: tandospirone, urapidil, ziprasidone, repinotan hydrochloride, xaliproden hydrochloride (SR-57746A), buspirone, flesinoxan, EMD-68843, DU-127090, gepirone, alnespirone, PNU-95666, AP-521, flibanserin, MKC-242, lesopitron, sarizotan hydrochloride, E-5842, SUN-N4057, Org-13011, Org-12966 and 8-OH-DPAT.

### Claim 3 (depends on 1)

The method of claim 1 wherein the disorder is selected from the group consisting of: AMD; RP and other forms of heredodegenerative retinal disease; retinal detachment and tears; macular pucker; ischemia affecting the outer retina; diabetic retinopathy; damage associated with laser therapy (grid, focal, and panretinal) including photodynamic therapy (PDT); trauma; surgical (retinal translocation, subretinal surgery, or vitrectomy) or light-induced iatrogenic retinopathy; and preservation of retinal transplants.

### Claim 4 (depends on 3)

The method of claim 3 wherein the disorder is AMD.

### Claim 5 (depends on 3)

The method of claim 3 wherein the compound is selected from the group consisting of: tandospirone, urapidil, ziprasidone, repinotan hydrochloride, xaliproden hydrochloride (SR-57746A), buspirone, flesinoxan, EMD-68843, DU-127090, gepirone, alnespirone, PNU-95666, AP-521, flibanserin, MKC-242, lesopitron, sarizotan hydrochloride, E-5842, SUN-N4057, Org-13011, Org-12966 and 8-OH-DPAT.

### Claim 6 (depends on 5)

The method of claim 5 wherein the disorder is selected from the group consisting of AMD, RP, and diabetic retinopathy.